CORAL SPRINGS, Florida, February 19, 2014 /PRNewswire/ --
Medical marijuana companies rapidly expand as restrictions lessen and demand increases: PetroTech Oil and Gas Inc. (OTC: PTOG), Webxu, Inc. (OTC: WBXU), Dewmar International BMC Inc. (OTC: DEWM), Nuvilex, Inc. (OTC: NVLX) and Chelsea Therapeutics Ltd. (NASDAQ: CHTP)
PetroTech Oil and Gas Inc. (OTC: PTOG) is pleased to announce today that they have set up a subsidiary company in Colorado, and Washington, to serve as the foundation for the company's entry into the emerging market for medical and recently legalized recreational marijuana in the United States. Through Legalizedpot.us, (LP.US Management Group Inc.) has been established to be the Management Company. This branch will specialize in managing the growers of legalized Marijuana and Hemp in the states where they are allowed to grow. "This management group is the first of its kind, we have three growers in Colorado and Two in Washington, that will be our first clients," said Steven Machat, the head of this new division.
To read the full press release, please click here: http://finance.yahoo.com/news/petrotech-oil-gas-inc-set-134500113.html
Eddie Schilb President of PTOG added, "Our progress in Nowata is moving fast, we have finished the cement casing, and will shoot the well today, February 19th, after which we will follow up with an updated press release and full report," he went on to say, "We are not abandoning our main focus of working the leases that we have and continuing to execute our plans on oil production." Please go to http://www.legalizepot.us to review the credentials of Steven Machat and Jae Benjamine.
Webxu, Inc. (OTC: WBXU) has announced that will expand its branded web and mobile development services into the industrial hemp industry. By working with Hemp, Inc. (OTC Pink: HEMP) and its subsidiaries, Webxu will be able to expand its reach and provide ongoing services in the areas of online web development and advertising initiatives for businesses in the industry. Matt Hill, Webxu CEO, said, "Webxu is looking forward to working with Hemp, Inc. and its subsidiaries including IHMMCC, Inc. Hemp, Inc. is a solid company with a strong presence in the hemp industry that strives to find new products and channels of distribution that fit within their industry.
Dewmar International BMC Inc. (OTC: DEWM) recently announced that it has entered into a one year distribution agreement with C+SWISS, the original and first hemp-based ice tea ever distributed in the United States. The agreement gives Dewmar the exclusive right to distribute the hemp-based ice tea nationwide to one of the world's largest retailers. The distribution agreement, effective immediately, continues Dewmar's recently announced initiatives to become one of the most successful licensees and creators of hemp-based products in the United States. The agreement was signed with Chill Drinks, LLC, a Miami, Florida-based company, and the creator of both the award-winning C+SWISS (hemp-based ice tea) and Chillo (hemp-based energy beverage). C+Swiss is an all-natural iced tea which is sold in both specialty and large retailers, including Whole Foods. The product is distributed in over 10 countries, experiencing over 30% sales growth in the past 7 years.
Nuvilex, Inc. (OTC: NVLX) is a biotechnology company that's focused on getting into late phase clinical trials for the treatment of advanced, inoperable pancreatic cancer, but it also expects to be a major player in the medical marijuana arena. And, to that end, last December, Nuvilex landed a leading figure in the medical marijuana field in Dr. Mark L. Rabe. Dr. Rabe was appointed as the Chairman of the Scientific Advisory Board of Medical Marijuana Sciences (MMS), the wholly-owned subsidiary Nuvilex formed to house its work in the Cannabis industry.
Chelsea Therapeutics Ltd. (NASDAQ: CHTP) recently announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval of NORTHERA[TM] (droxidopa)for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH. NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the "feeling that you are about to black out" in adult patients with symptomatic NOH caused by primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand two hundred fifty dollars for news coverage of the current press release issued by PTOG by a non-affiliated third party.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group, LLC